CJC-1295 vs Ipamorelin — Research Comparison

CJC-1295 and ipamorelin are the two most-cited synergistic growth-hormone-axis research peptides in the published literature. They act on different receptors at the pituitary — CJC-1295 is a GHRH analog, ipamorelin is a ghrelin-receptor (GHS-R) agonist — and their combination produces a larger GH pulse than either alone. This comparison summarises the published literature relevant to laboratory research.

At-a-glance comparison

| Attribute | CJC-1295 | Ipamorelin | |---|---|---| | Class | GHRH analog | GHRP / ghrelin-receptor (GHS-R) agonist | | Receptor target | Pituitary GHRH receptor | Pituitary GHS-R (ghrelin receptor) | | Variants | With DAC (~8 day) and without DAC (~30 min) | Single form (~2 hour half-life) | | Cortisol / prolactin release | Minimal | Minimal (cleanest of the GHRPs) | | Synergy with the other class | Yes — additive GH pulse with GHRPs | Yes — additive GH pulse with GHRH analogs | | Typical research dosing | 100 mcg (no-DAC) or 1-2 mg weekly (DAC) | 100-300 mcg per administration |

Mechanism — two receptors, one pulse

CJC-1295 binds the pituitary GHRH receptor and stimulates endogenous GH release, preserving pulsatility and negative-feedback regulation by somatostatin. Ipamorelin binds the ghrelin receptor (GHS-R) on the same pituitary somatotrophs but through a different signalling cascade, and in addition suppresses somatostatin tone. The two pathways are additive, which is the most-cited reason for their combined use in research models.

Pharmacokinetics

Ipamorelin has a plasma half-life of approximately 2 hours. CJC-1295 exists in two research variants: without DAC (drug-affinity complex) it shares the short ~30-minute half-life of native GHRH (1-29); with DAC it covalently binds serum albumin and exhibits a half-life of approximately 8 days, producing sustained elevation of basal GH and IGF-1 across the dosing interval.

Published research highlights

The two peptides are most-cited together in published research because of their additive GH-release effect. Ipamorelin is the cleanest of the GHRPs in the published literature — minimal cortisol or prolactin release at standard research doses, unlike GHRP-2 or GHRP-6. CJC-1295 with DAC is most-cited for producing sustained, day-long elevation of IGF-1 in research models.

Where they overlap, where they don't

Overlap: both ultimately drive endogenous GH release from pituitary somatotrophs, both preserve the GH-axis feedback loop. Divergence: they act on different receptors via different signalling cascades, which is why their effects on GH release are additive rather than redundant.

Choosing one for a research protocol

For research that isolates GHRH-receptor biology or requires sustained day-long IGF-1 elevation (DAC variant), CJC-1295 is the appropriate reference. For research that isolates ghrelin-receptor biology, requires a clean side-effect profile, or pairs with a GHRH analog for additive GH release, ipamorelin is the appropriate reference. The two are most commonly studied in combination.

Frequently asked research questions

Why are CJC-1295 and Ipamorelin combined in research?

Because they bind different receptors on the same pituitary cells via different signalling cascades, their effects on GH release are additive rather than redundant — the combined pulse is larger than either alone in published research.

What's the difference between CJC-1295 with DAC and without DAC?

Without DAC, CJC-1295 has a half-life of approximately 30 minutes and is used to study acute pulses. With DAC (drug-affinity complex), CJC-1295 covalently binds serum albumin and exhibits a half-life of approximately 8 days, producing sustained elevation of basal GH and IGF-1.

Does ipamorelin raise cortisol or prolactin?

Ipamorelin is the most-cited GHRP for its selectivity — minimal cortisol or prolactin release at standard research doses, distinguishing it from GHRP-2 and GHRP-6 in the published literature.

Can either replace exogenous [HGH](/research/hubs/hgh)?

Both stimulate endogenous GH release; they do not deliver exogenous HGH. The two approaches produce different pharmacological profiles — endogenous secretagogues preserve pulsatility and feedback; exogenous somatropin replaces both. They are studied for different research questions.

Related research

• CJC-1295 research hub → /research/hubs/cjc-1295
• Ipamorelin research hub → /research/hubs/ipamorelin
• HGH vs Tesamorelin → /research/hgh-vs-tesamorelin-research-comparison
• Tesamorelin vs Sermorelin → /research/tesamorelin-vs-sermorelin-research-comparison

Research use only. All content on this page is provided for in-vitro and laboratory research purposes. No statements are intended for, and nothing on this page should be construed as, medical advice or a recommendation for human consumption.